Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.65 |
| ▸ | ATM | Q13315 | 1/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | FNTA | P49354 | 3/20 | 0.62 |
| ▸ | FNTB | P49356 | 3/20 | 0.62 |
| ▸ | SQLE | Q14534 | 3/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9017173 | 1.00 | KMT2A (0.73) | KMT2AKDM4EATMALOX15MAPT | |
| SCHEMBL7944866 | 1.00 | KMT2A (0.73) | KMT2AKDM4EATMALOX15MAPT | |
| SCHEMBL7934894 | 1.00 | KMT2A (0.73) | KMT2AKDM4EATMALOX15MAPT | |
| SCHEMBL14236792 | 1.00 | KMT2A (0.73) | KMT2AKDM4EATMALOX15MAPT | |
| SCHEMBL7946216 | 1.00 | KMT2A (0.73) | KMT2AKDM4EATMALOX15MAPT | |
| SCHEMBL3111482 | 1.00 | KMT2A (0.73) | KMT2AKDM4EATMALOX15MAPT | |
| SCHEMBL14236831 | 1.00 | KMT2A (0.73) | KMT2AKDM4EATMALOX15MAPT | |
| SCHEMBL157509 | 1.00 | KMT2A (0.73) | KMT2AKDM4EATMALOX15MAPT | |
| SCHEMBL112856 | 1.00 | KMT2A (0.73) | KMT2AKDM4EATMALOX15MAPT | |
| SCHEMBL14236813 | 1.00 | KMT2A (0.73) | KMT2AKDM4EATMALOX15MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 244 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4594744-A1 | METHOD FOR DETECTING BED BUGS | CENTRE SCIENTIFIQUE ET TECHNIQUE DU BATIMENT (FR) | 2025-08-06 | — | — | EP | claimed |
| CN-119547794-A | Composition for repelling and killing ticks as well as preparation method and application thereof | 石河子大学 | 2025-03-04 | — | — | CN | claimed |
| CN-119320670-A | High-quality geranylacetone composition and application | 万华化学集团股份有限公司 | 2025-01-17 | — | — | CN | claimed |
| WO-2025013888-A1 | AROMA CHEMICAL COMPOSITION AND MENSTRUAL CYCLE MARKER | 国立大学法人 東京大学 | 2025-01-16 | — | — | WO | claimed |
| WO-2024069385-A1 | METHOD FOR DETECTING BED BUGS | CENTRE SCIENTIFIQUE ET TECHNIQUE DU BATIMENT (FR) | 2024-04-04 | — | — | WO | claimed |
| CN-115047127-B | Method for identifying NFC and FC orange juice by utilizing volatile metabonomics technology | 中国检验检疫科学研究院 | 2024-03-08 | — | — | CN | claimed |
| US-20240018505-A1 | ENZYMATIC MONOCYCLIZATION OF ACYCLIC MONOTERPENOIDS | UNIVESITAET STUTTGART (DE) | 2024-01-18 | — | — | US | claimed |
| EP-4247945-A1 | ENZYMATIC MONOCYCLIZATION OF ACYCLIC MONOTERPENOIDS | Universität Stuttgart (DE) | 2023-09-27 | — | — | EP | claimed |
| CN-116615555-A | Enzymatic monocyclization of acyclic monoterpenes | 斯图加特大学 | 2023-08-18 | — | — | CN | claimed |
| CN-112924609-B | Method for analyzing volatile aroma components contained in bead blasting filter stick | 福建中烟工业有限责任公司 | 2023-02-03 | — | — | CN | claimed |
| EP-2535323-A1 | Hydrogenation of ketones having at least a carbon-carbon double bond in the gamma-,delta-position | DSM IP Assets B.V. (NL) | 2012-12-19 | — | — | EP | claimed |
| EP-1828159-B1 | ASYMMETRIC HYDROGENATION OF ALKENES USING CHIRAL IRIDIUM COMPLEXES | DSM IP ASSETS BV (NL) | 2011-08-17 | — | — | EP | claimed |
| EP-1337229-B1 | IMMOBILISATION OF ACTIVE AGENTS ON FIBRES | HENKEL AG & CO KGAA (DE) | 2009-09-30 | — | — | EP | claimed |
| EP-1670314-A4 | METHODS AND COMPOSITIONS COMPRISING DIAMINES AS NEW ANTI-TUBERCULAR THERAPEUTICS | SEQUELLA INC (US) | 2009-02-25 | — | — | EP | claimed |
| US-20080039638-A1 | Asymmetric Hydrogenation of Alkennes Using Chiral Iridium Complexes | DSM IP ASSETS B.V. (NL) | 2008-02-14 | — | — | US | claimed |
| EP-1828159-A1 | ASYMMETRIC HYDROGENATION OF ALKENES USING CHIRAL IRIDIUM COMPLEXES | DSMIP Assets B.V. (NL) | 2007-09-05 | — | — | EP | claimed |
| WO-2006066863-A1 | ASYMMETRIC HYDROGENATION OF ALKENNES USING CHIRAL IRIDIUM COMPLEXES | DSM IP ASSETS B.V. (NL) | 2006-06-29 | — | — | WO | claimed |
| EP-1670314-A2 | METHODS AND COMPOSITIONS COMPRISING DIAMINES AS NEW ANTI-TUBERCULAR THERAPEUTICS | Sequella, Inc. (US) | 2006-06-21 | — | — | EP | claimed |
| US-20050113574-A1 | Methods and compositions comprising diamines as new anti-tubercular therapeutics | SEQUELLA, INC. | 2005-05-26 | — | — | US | claimed |
| WO-2005034857-A2 | METHODS AND COMPOSITIONS COMPRISING DIAMINES AS NEW ANTI-TUBERCULAR THERAPEUTICS | SEQUELLA, INC. (US) | 2005-04-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039638-A1 | Asymmetric Hydrogenation of Alkennes Using Chiral Iridium Complexes | SQLE, FADS1, FADS2 | KMT2A 3003/4885KDM4E 3611/4885ATM 1790/4885 |
| US-20050113574-A1 | Methods and compositions comprising diamines as new anti-tubercular therapeutics | C5, DDC, SAT1 | KMT2A 2113/4885KDM4E 1180/4885ATM 2012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.